incontinence and mucus loss in the rectum mapping. For the IG-IMRT patients only mucus loss was significant in the anus mapping, while both mucus loss and proctitis were significant in the rectum mapping. Results for proctitis are illustrated for 3D-CRT (44% incidence) in the anus mapping ( Fig. 1e,  p=0 .01) and for IG-IMRT (27% incidence) in the rectum mapping ( Fig. 1f, p<0 .01). Note that the largest dose differences are not necessarily most significant. In a region with large dose variations, random permutations can lead to large differences by chance. Figs. 1c and 1e Purpose/Objective: Acute dysphagia is a common toxicity, associated with (chemo)radiotherapy for head and neck cancer, with substantial quality of life implications. 'Late' dysphagia is thought to result predominantly as a consequence of acute toxicity and associated interventions. There are currently limited dose-response data on radiationinduced acute dysphagia in the literature. The aim of this study was to train and validate NTCP models, providing reliable tools to accurately predict the severity of acute dysphagia for individual patients. Materials and Methods: Predictive models of moderate or worse (Common Terminology Criteria for Adverse Events grade 2 or 3) and severe (grade 3) acute dysphagia were trained using data from six clinical trials featuring a range of primary disease sites and treatment techniques. Toxicity outcome was defined as the peak grade of toxicity, which was scored weekly throughout radiotherapy and up to 4 weeks post-treatment and additionally at 8 weeks posttreatment. 266 patients were included in the analysis after excluding patients with two or more consecutive missing toxicity measurements. Pharyngeal mucosa dose-volume parameters, concomitant treatment and clinical factors were considered as model covariates. Logistic regression was used for classification. Lasso-and ridge-regularisation, classweighting and cross-validated grid search were employed. The models were validated internally (with nested 5-fold stratified shuffle split cross-validation) and externally (on independent data) to measure their performance, using area under the receiver operating characteristic curve as the performance metric. Results: Figure 1 summarises the dose-volume data.
Model diagnostics using learning curves showed that the severe dysphagia model was under-fitting the data. It was thought that this might be due to insufficient characterisation of concurrent chemotherapy. The model was retrained using 115 patients who did not receive concurrent chemotherapy. Table 1 
